Weiss Ratings Reaffirms "Sell (D-)" Rating for MiNK Therapeutics (NASDAQ:INKT)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for MiNK Therapeutics (NASDAQ:INKT), indicating ongoing concerns about the company's financial health.
• Despite multiple analyst reviews, MiNK Therapeutics has received a mix of ratings, with one "Strong Buy," two "Buy," one "Hold," and two "Sell" ratings, resulting in a consensus rating of "Hold" with a price target of $37.50.
• MiNK Therapeutics reported a quarterly loss of ($1.06) EPS, missing analyst expectations, while analysts project an average of (-2.75 EPS) for the current fiscal year.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Several other research analysts also recently commented on INKT. William Blair downgraded shares of MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Friday, July 11th. Wall Street Zen lowered shares of MiNK Therapeutics to a "strong sell" rating in a report on Saturday, August 23rd. B. Riley upgraded shares of MiNK Therapeutics to a "strong-buy" rating in a research report on Friday, July 18th. Zacks Research cut shares of MiNK Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday, August 18th. Finally, HC Wainwright raised shares of MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 target price on the stock in a research note on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $37.50.

MiNK Therapeutics Price Performance

Shares of NASDAQ:INKT opened at $14.59 on Wednesday. The company has a market capitalization of $65.99 million, a P/E ratio of -5.07 and a beta of 0.33. MiNK Therapeutics has a 1 year low of $4.56 and a 1 year high of $76.00. The business's 50 day simple moving average is $14.57 and its 200 day simple moving average is $11.68.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.51). On average, sell-side analysts anticipate that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.